U.S. Public Policy: Will the Inflation Reduction Act Actually Reduce Inflation?

U.S. Public Policy: Will the Inflation Reduction Act Actually Reduce Inflation?

The Senate just passed the Inflation Reduction Act which seeks to fight inflation on a variety of fronts, but the most pressing question is, will the IRA actually impact inflation?


-----Transcript-----


Michael Zezas: Welcome to Thoughts on the Market. I'm Michael Zezas, Morgan Stanley's Head of U.S. Public Policy Research and Municipal Strategy.


Ellen Zentner: And I'm Ellen Zentner, Morgan Stanley's Chief U.S. Economist.


Michael Zezas: And on this special episode of Thoughts on the Market, we'll discuss the Inflation Reduction Act, or IRA, with a focus on its impact on the U.S. economic outlook. It's Wednesday, August 10th, at noon in New York.


Michael Zezas: So, Ellen, the Senate just passed the Democrats Inflation Reduction Act on a party line vote. And we know this has been a long awaited centerpiece to President Biden's agenda. But let me start with one of the more pressing questions here; from your perspective, does the Inflation Reduction Act reduce inflation? Or maybe more specifically, does it reduce inflation in a way that impacts how the Fed looks at inflation and how markets look at inflation?


Ellen Zentner: So for it to impact the Fed today and how the markets are looking at inflation, it really has to show very near term effects here, where the IRA focuses more on longer term effects on inflation. So today we've got recent inflation report that came out this week showing that inflation moved lower, so softened. Especially showing the effects of those lower energy prices, which everyone notices because you go and gas up at the pump and so, you know right away what inflation is doing. And that's led to some more optimism from households. That at least gives the Fed some comfort, right, that they're doing the right thing here, raising rates and helping to bring inflation down. But there's a good deal more work for the Fed to do, and we think they raise rates by another 50 basis points at their September meeting. The rates market also took note of some of the inflation metrics of late that are looking a little bit better. But still, it's not definitive for markets what the Fed will do. We need a couple of more data points over the next few months. So the IRA is just a completely separate issue right now for the Fed and markets because that's going to be in the longer run impact.


Michael Zezas: So the bill is constructed to actually pay down the federal government deficit by about $300 billion over 10 years, and conventional wisdom is that when you're reducing deficits, you're helping to calm inflation. Is that still the case here?


Ellen Zentner: So it's still the case in general because it means less government debt that has to be issued. But let's put it in perspective, $300 billion deficit reduction spread over ten years is 30 billion a year in an economy that's greater than 20 trillion. And so it's very difficult to see.


Michael Zezas: Okay, so the Inflation Reduction Act seems like it helps over the long term, but probably not a game changer in the short term.


Ellen Zentner: That's right.


Michael Zezas: Let's talk about some of the more specific elements within the bill and their potential impact on inflation over the longer term. So, for example, the IRA extends Affordable Care Act subsidies. It also allows Medicare to negotiate prices for prescription drugs, or at least some prescription drugs, for the first time. How do you view the impacts of those provisions?


Ellen Zentner: So these are really the provisions that get at the meat of impacting inflation over the longer run. And I'll focus in on health care costs here. So specifically, drug prices have been quite high. Being able to lower drug prices helps lower income households, that helps older cohorts, and the cost of medical services gets a very large weight in overall consumer inflation and it gets a large weight because we spend so much on it. The other thing I'd note here, though, is that since it allows Medicare to negotiate prices for some drugs for the first time, well, that word negotiate is key here. It takes time to negotiate price changes, and that's why this bill is more something that affects longer run inflation rather than near term.


Michael Zezas: Right. So bottom line, for market participants, this Inflation Reduction Act might ultimately deliver on its name. But if you want to understand what the Fed is going to do in the short term and how it might impact the rates markets, better off paying attention to incoming data over the next few months. It's also fair to say there's other market effects to watch emanating from the IRA, namely corporate tax effects and spending on clean energy. Those are two topics we're going to get into in podcasts over the next couple of weeks.


Michael Zezas: Ellen, thanks for taking the time to talk.


Ellen Zentner: Great speaking with you, Michael.


Michael Zezas: As a reminder, if you enjoy Thoughts on the Market, please take a moment to rate and review us on the Apple Podcasts app. It helps more people find the show.

Avsnitt(1587)

How Japan’s Stablecoin Could Reshape Global Finance

How Japan’s Stablecoin Could Reshape Global Finance

Our Japan Financials Analyst Mia Nagasaka discusses how the country’s new stablecoin regulations and digital payments are set to transform the flow of money not only locally, but globally.Read more in...

31 Okt 20254min

Why Shutdown Standoff Raises Stakes for Healthcare

Why Shutdown Standoff Raises Stakes for Healthcare

Our analysts Ariana Salvatore and Erin Wright explain the pivotal role of healthcare in negotiations to end the government shutdown.Read more insights from Morgan Stanley.----- Transcript -----Ariana ...

30 Okt 20255min

M&A Poised to Gain Momentum

M&A Poised to Gain Momentum

Our Head of Corporate Credit Research Andrew Sheets explains why the recent revival of M&A activity has room to accelerate.Read more insights from Morgan Stanley.----- Transcript -----Andrew Sheets: W...

29 Okt 20254min

A Turnaround in Sight for Healthcare?

A Turnaround in Sight for Healthcare?

Our U.S. Biotech and Biopharma analysts Sean Laaman and Terence Flynn discuss the latest developments that could be positioning the healthcare sector for strong outperformance.Read more insights from ...

28 Okt 20255min

Will the Stock Market Rally Continue?

Will the Stock Market Rally Continue?

Our CIO and Chief U.S. Equity Strategist Mike Wilson discusses the outlook for stocks after the preliminary U.S.-China trade agreement and ahead of the Fed meeting and big tech earnings.Read more insi...

27 Okt 20253min

What Happens to Software Developers as AI Can Code?

What Happens to Software Developers as AI Can Code?

Our U.S. Software Analyst Sanjit Singh explains how AI is reshaping software development and why the future for the sector may be brighter – and busier – than ever.Read more insights from Morgan Stanl...

24 Okt 20254min

Should AI Spending Worry Investors?

Should AI Spending Worry Investors?

Our Head of Corporate Credit Research Andrew Sheets wades into the debate around whether the boom in artificial intelligence investment is a warning sign for credit markets. Read more insights from Mo...

23 Okt 20253min

The Next Turning Points in Tech

The Next Turning Points in Tech

Our analysts Brian Nowak, Keith Weiss and Matt Bombassei break down the most important tech insights from Morgan Stanley’s Spark Private Company Conference and industry shifts that will likely shape 2...

22 Okt 202511min

Populärt inom Business & ekonomi

framgangspodden
varvet
badfluence
rss-jossan-nina
rss-borsens-finest
rss-svart-marknad
uppgang-och-fall
avanzapodden
svd-tech-brief
lastbilspodden
rss-dagen-med-di
fill-or-kill
borsmorgon
rss-inga-dumma-fragor-om-pengar
bathina-en-podcast
rss-kort-lang-analyspodden-fran-di
kapitalet-en-podd-om-ekonomi
rss-den-nya-ekonomin
rss-wallnor-pm
affarsvarlden